


CERTIFICATE OF ANALYSIS No.: 2021-2915

CLIENT



SAMPLE

CBD CRYSTALLINE POWDER



Sample condition: SUITABLE
Sample ID: 21150
Sample type: Crystal
Batch No.: CB99021005A

Work order: 2021-104572
Analysis ID: 2021_002
Method ID: PHL_RPC_12C
Method SOP: MET-002

Sample received: 05/01/2021
Start of analysis: 05/01/2021
End of analysis: 06/01/2021
Analyst: Janez Gerdenc

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	0.351	0.063	
CBDA - Cannabidiolic acid	< LOQ	n/a	
CBGA - Cannabigerolic acid	< LOQ	n/a	
CBG - Cannabigerol	< LOQ	n/a	
CBD - Cannabidiol	99.5	5.0	
THCV - Tetrahydrocannabivarin	< LOQ	n/a	
CBN - Cannabinol	< LOQ	n/a	
CBC - Cannabichromene	< LOQ	n/a	
THC - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	
THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
8-THC - Δ-8-Tetrahydrocannabinol *	< LOQ	n/a	
CBL - Cannabicyclol *	< LOQ	n/a	

The results marked by * relate to non-accredited activity.

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from [redacted]. The document does not substitute any other legal document.

Date issued:

06/01/2021

Approved by:

mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate

